We would love to hear your thoughts about our site and services, please take our survey here.
What do we think the time frame is for results from phase one trials from here?
This surely has all the signs of a placing now?
Well Lowey it has actually gone down since the RNS dropped so yes....
How the hell are we on a downturn after such positive news?
Just gone clinical and CBR in the pipeline and we're on a downward slide. I was expecting a steady trickle up to 6-7p over the next few months at least.
Thank you HH
I originally got invested as friends in work used to pick random shares as a bit of a gamble as a bit of fun more than anything. I happened upon hemo by chance and have built my holding slowly based mostly on the good feeling that it can make a difference.
I've found it difficult to easily explain to friends why it could be a game changer. paticularly as science wasn't my strong point in school. I will take this as a boot up the backside to broaden my knowledge.
any criticism i have ever labelled hasn't ever been at the technology but the time processes in getting things through government agency's. It rarely goes on time. Same as when my missus says she'll be arrving or be ready I apply the rule of 3 and multiply the stated or expected time by 3. I like to apply this to hemo time frames and anything less is then a bonus. I tend to have a beer waiting for the missus so i guess i'll sit back and enjoy a beer whilst hopefully vlad and team do the hard work.
thanks again for your help, i watch CBR in particular with great anticipation. an old school friend is currently suffering stage 4 cancer and looking for alternative therapies. Just the thought of something like CBR being in the pipeline is promising as a big middle finger to cancer in the future.
HH I asked because I struggle to explain it in terms people understand when I talk about being invested.
I struggle with a lot of it myself if I’m honest. I’m just hopeful I’m invested in a share that may make some big differences in people lives.
I’ve never been adamant that things will or won’t happen. More sceptical on time frames, particularly where government bodies become involved.
Would someone be kind enough to break down the technology in layman's terms for CDX, CBR and Car-T?
Would any of these technologies be potentially used against a broad range of cancers in the future? I.e. breast cancer, long cancer etc?
Has anyone researched who else prevail have invested in and with what results?
Agreed Pingu, Prevail must have done due diligence and had firm reassurance from Hemo that there is plenty in the pipeline either on the FDA approval or CBR breaking ground soon
I’m by no means an expert but In my opinion I think we’ll be waiting at least twice as long as we expect for the green light from the FDA.
You’ve got to think that anything governmental will not be quick. Regardless of whether it’s straightforward or now,
So I’m thinking it’s two months from the hold just for Hemo to get revised application to them and then at least two months probably 4 from there that we get an answer from the FDA again.
Thanks @jezconnor I'm not sure that Vlad's comment suggest either way whether its admin or product. It could be a simple lack of information provided that they didn't realize the FDA wanted rather than a product issue. Although i guess it could be a bit of both.
I'm not the most versed trader so seeking the experts advice.
Have Hemo had to submit an INdy to the DFA before?
Just wondering because many seem to think that Vlad is a brilliant scientist but not the greatest CEO and perhaps the paperwork side of things isn't the business strong point. If they'd never submitted to the FDA before perhaps that is what the hold up is and that its like of skill/knowledge in the requirements that is the issue rather than the science being in question?
Hopefully this is something as simple as missing paperwork and some inexperience on hemo's part in understanding exactly what is required by the FDA.
Its a strong buy if we're still confident the science is sound and going on Vlad's past its more likely to be administrative and communicative rather than scientifically flawed
I don’t often post about but I know most are expecting there to have been an RNS re; independent testing by now.
Just wondering if that’s because we expect Indy testing to have started immediately but I’m guessing we dance to the beat of their drum not the other way round so could quite easily be waiting for the independent testing to start still as they could be employed in other projects before ours?
Could even be 14:30 today. its imminent and Vlad does seem buoyant lol
That’s a weird quote dealer. Explain to me how your top shagger status means that War is now good for the sale process and makes it more likely than it was before…..
This board is weird at times,
Think we all knew this was coming, and I’d say this now ends the chance of a sale anytime soon or even this year. Now comes a very long term hold
I'd say that RNS tells us no chance of final sale this year. Going to be next March at the earliest before we se any news.
To be fair I do agree with a lot you say mate, if Vlads intention in going it alone is because it’s quicker then fair play as I can imagine there is a lot of red tape and waiting for answers when dealing with big pharma.
I know there are concerns with Vlad to ceo not Vlad the scientist so hopefully he’s getting the results and leaving the admin and BS to someone else.
I really do hope this succeeds for the health reasons more than the SP and myself making a profit as the amount of shares I have means my return probably isn’t going to mean I can retire.
Jimihendrix I agree, it’s not shooting up because the sentiment would be with Eli doing the licensing not Hemo, couple that with the inevitable long time scale to the next positive RNS then there are better places investors can put their money atm. This isn’t rising from its current mark this year IMO.
I know jhfh is championing the share a lot and I agree with the potential based on what we know but the bug question is that EL the big pharma with more knowledge than us isn’t piling in themselves on the product and there must be a reason why. And that’s what the market must be thinking too.